FibroBiologics, Inc. (Nasdaq: FBLG), a biotech firm holding over 270 patents, disclosed promising preclinical findings. The results indicate that utilizing human dermal fibroblast (HDF) spheroids topically can alter the burn wound environment positively. This treatment approach demonstrated the ability to decrease damaging inflammation, modify immune cell response, and lessen indicators of scar formation within eight days post-injury.